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Abstract
Topiramate is an antiepileptic drug known to ameliorate insulin resistance besides reducing body weight. Albeit liver plays a
fundamental role in regulation of overall insulin resistance, yet the effect of topiramate on this organ is controversial and is
not fully investigated. The current work aimed to study the potential hepatic molecular mechanistic cassette of the anti-
insulin resistance effect of topiramate. To this end, male Wistar rats were fed high fat/high fructose diet (HFFD) for 10 weeks
to induce obese, insulin resistant, hyperglycemic animals, but with no overt diabetes. Two HFFD-groups received oral
topiramate, 40 or 100 mg/kg, for two weeks. Topiramate, on the hepatic molecular level, has opposed the high fat/high
fructose diet effect, where it significantly increased adiponectin receptors, GLUT2, and tyrosine kinase activity, while
decreased insulin receptor isoforms. Besides, it improved the altered glucose homeostasis and lipid profile, lowered the ALT
level, caused subtle, yet significant decrease in TNF-a, and boosted adiponectin in a dose dependent manner. Moreover,
topiramate decreased liver weight/, visceral fat weight/, and epididymal fat weight/body weight ratios. The study proved
that insulin-resistance has an effect on hepatic molecular level and that the topiramate-mediated insulin sensitivity is
ensued partly by modulation of hepatic insulin receptor isoforms, activation of tyrosine kinase, induction of GLUT2 and
elevation of adiponectin receptors, as well as their ligand, adiponectin, besides its known improving effect on glucose
tolerance and lipid homeostasis.
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Introduction
Westernized diet, prevalent in modern society, is characterized
by the increased consumption of high fat diet (HFD) along with
fructose as a common sweetener. This type of food, together with
the slothful lifestyle, participates in the amplification of the global
wave of obesity, which is invariably associated with a constellation
of pathological perturbations, among which is insulin resistance
(IR) [1]. IR is manifested by the failure of endogenous insulin to
hinder hepatic gluconeogenesis and to induce glucose peripheral
uptake. Such dysfunction is compensated by hyperinsulinemia,
and associated with alteration in glucose and lipid homeostasis,
with or without overt diabetes [2]. Moreover, this type of diet
frequently induces hepatic steatosis, which accounts for hepatic
insulin resistance [3], and favors muscular fat storage, as well as
visceral fat deposition [1], facilitating thus, the development of
peripheral insulin resistance [4]. In addition, HFD-induced
increased white adipose tissue (WAT) participates in the induction
of whole body insulin resistance, via increasing the secretion of the
pro-inflammatory cytokine, TNF-a, which impairs insulin signal-
ing [5]. On the other hand, adiponectin, another adipohormone
secreted also by adipocytes, is present in low concentration in
obesity-insulin resistant states [6]. Furthermore, fructose, the main
sweetener of westernized diet, is deemed to be a contributing
factor to these epidemic disorders [7], where exposure of liver to
such large quantities of fructose and fats leads to rapid stimulation
of lipogenesis with the accumulation of triglycerides (TGs) that
contribute, in turn, to reduced insulin sensitivity and hepatic
insulin resistance/glucose intolerance [8].
Peripheral insulin resistance emanates from interplay between
three major organs, viz., liver, adipose tissue and skeletal muscles,
with altered insulin signaling that stems from altered insulin
receptors and post-receptor defects at the molecular level. These
include alterations in the relative abundance of the two insulin
receptor isoforms, decrease in insulin affinity to its receptors,
improper insulin receptor kinase activity, decrease in autophos-
phorylation, and abnormalities in glucose transporter translocation
and activation [9].
Topiramate (TPM), a sulfamate-substituted monosaccharide,
is a neurotherapeutic agent currently indicated for the
management of epilepsy and migraine, and is documented to
possess weight reducing properties, as well as insulin resistance
improving effects [10]. Moreover, TPM has been reported to
lower TGs and circulating FFAs, and to increase adiponectin
levels [11]. Albeit liver is a cornerstone in the maintenance of
insulin sensitivity and glucose metabolism, yet most studies on
TPM were much more concerned with studying the effects on
skeletal muscles and adipose tissue. Hence, the goal of this study
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mechanisms related to insulin sensitivity and its modulation by
TPM. To this end, a murine obese-insulin resistant model, but
not with overt diabetes, was adopted to evaluate the effect of
TPM on some hepatic molecular elements, besides the usual
glucose/lipid homeostasis parameters, as well as the levels of the
two contradictory cytokines, viz., adiponectin and TNF- a.
Materials and Methods
1. Drugs and Chemicals
Topiramate (Topamax) was purchased from Janssen Cilag Co.
(AG, Schaffhausen, Switzerland), and fructose was obtained from
El-Nasr Chemical-Co. (Abou Zaabal, Cairo, Egypt). Cholesterol
and lard were obtained from commercial sources and were of
analytical grades.
2. Animals
Adult male Wistar rats (80–120 g) were purchased from
National Research Center Laboratory (Cairo, Egypt). Rats were
singly caged with free access to water and commercially available
normal rat pellet diet prior to dietary manipulation. Animals were
kept on a 12 hr light/dark cycle, and constant environmental
conditions. Experimental design and animal handling were
approved by the Research Ethical Committee of the Faculty of
Pharmacy, Cairo University, Cairo, Egypt.
3. Development of Obese Insulin-resistant Rats
After three days of acclimatization, fifty rats were divided into
two dietary regimen-groups, normal fat diet (NFD, n=10)
[3150 cal/g; fat (5%), protein (21%), carbohydrate as starch
(60%), fibers (3%), vitamins and minerals (1%)], and high fat/high
fructose diet (HFFD, n=40) [5300 cal/g; fat (15% composed of
10% as lard and 1% cholesterol powder), protein (21%),
carbohydrate as fructose (60%), fibers (3%), vitamins and minerals
(1%) [12]. Diet manipulation lasted for 10 weeks until significant
weight gain and insulin resistance were achieved. Animals were
monitored once a week for weight gain along with alterations in
fasting serum glucose, triglyceride (TG), and total cholesterol (TC).
After 10 weeks, insulin level and glucose tolerance test (GTT) were
undertaken, and only rats with increased weight gain, impaired
glucose tolerance, hyperinsulinemia, hypertriglyceridemia, and
hypercholesterolemia were considered obese/insulin-resistant and
were used in the study.
4. Intra-peritoneal Glucose Tolerance Test (IPGTT)
The test was performed to confirm the state of insulin
resistance, where after six hours of fasting animals from both
groups, viz., NFD, and HFFD, were injected by glucose (2 g/kg,
i.p). Droplets of blood from the tail vein were then drawn at 0
(prior to glucose load), 30, 60, 90 and 120 minutes (after glucose
load) for glucose assay. AUC was calculated for blood glucose
during the IPGTT according to the following equation:
AUC=0.256(fasting value)+0.56(1/2 h value)+0.756(1 h va-
lue)+0.56(2 h–value) [13].
5. Experimental Design
Rats with confirmed IR (n=30) were further subdivided into
three groups, two of them were given daily oral doses of either
TPM 40 mg/kg ([14], HFFD/TPM40), or TPM 100 mg/kg ([15],
HFFD/TPM100) for 2 weeks. The last 10 IR rats received saline
and served as positive control group, while the NFD fed rats
represented the negative normal control group and received saline,
as well. Pair feeding was implemented to control for the food
restriction effects of TPM. Pair-fed rats consumed equal portions
of food as TPM-treated rats daily, ranging from 13–15 g/day.
All four groups continued their indicated diet till the end of
experiment and the last dose of any treatment was given 24 hours
before killing the rats, which were fasted 18 hours before the time
of carnage, to minimize feeding induced variations in lipid and
glucose pattern.
To exclude the possible effect of both dose levels of TPM (40
and 100 mg/kg) on the negative normal control rats (NFD), a
preliminary study was performed and the assessed parameters are
reported in Table 1.
6. Collection of Serum Samples for Analysis
At the time of carnage, animals were weighed and blood was
collected from the tail vein under brief ether anesthesia, and
centrifuged (8006g, 4uC, 20 min) to separate sera. Animals were
then sacrificed by cervical dislocation and liver, visceral fat and
epididymal fat were carefully dissected out and weighed. Sera were
used to determine glucose [16], fructosamine [17], TGs [18], TC
[19], and ALT using commercially available Randox colorimetric
reagent kits (Antrim, U.K). Insulin and adiponectin levels were
estimated using RIA kit (Linco Research, St Charles, MO,USA)
[20], while TNF-a was measured using ELISA kit (R&D systems,
Minneapolis, USA). Homeostasis Model Assessment-index
(HOMA-index) was calculated according to the following equa-
tion: [(glucose concentration (mmol/L) 6 Insulin (mU/L)/22.5]
[21].
7. Tissue Weights
The changes in body weight (BW) were monitored every week,
and the liver weight (LW), visceral fat weight (VFW) and
epididymal fat weight (EFW) were expressed as a ratio of body
weight (BW) multiplied by a factor of 100.
8. Tissue Extracts
For the following assays livers were rinsed in ice-cold phosphate
buffer saline (PBS, 0.02 mol/l, pH 7.0–7.2) to remove excess
blood thoroughly and weighed before homogenization. The
minced liver tissues (0.5 g) were homogenized in 5 ml of PBS
and the resulting suspension was subjected to two freeze-thaw
cycles to break the cell membrane then sonicated with an
ultrasonic cell disrupter. Afterwards, homogenates were centri-
fuged for 5 minutes at 50006g and the supernatant was collected,
measured and immediately divided into aliquots and stored at
220uC for the ELISA assay of adiponectin receptor R1and R2
(Uscn Life Science Inc. Wuhan, China), and GLUT2 (glucose
transporter 2 ELISA kit,Wuhan, China).
8.1. Detection range for adiponectin R1and R2. For
adiponectin R1the standard curve concentrations used for ELISA
were 10, 5, 2.5, 1.25, 0.625, 0.312, and 0.156 ng/mL, while those
of adiponectin R2 were 20, 10, 5, 2.5, 1.25, 0.625, and 0.312 ng/
mL.
8.2. Determination of tyrosine kinase activity. Dissected
liver tissues, after determination of the protein content to contain
1–5610
6 cells, were washed with PBS and spun at room
temperature for 5 min. at 3006g and then the cells were
recovered as pellets. One ml of extraction buffer was added to
each sample, and the pellet was then suspended by vortex gently.
The supernatant was recovered as the samples by spinning at 4uC
for 10 min. at 10,0006g and remained stable at - 80uC for few
days. The enzymatic activity was assessed according to the
procedures stated by the Universal Tyrosine Kinase Assay Kit
(TAKARA BIO INC., Tokyo, Japan).The activity of enzyme is
based on the activity of recombinant c-Src, where one unit (U) of
Topiramate and Hepatic Insulin Sensitizing Effect
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of phosphate into the substrate in 1 min. The activity of protein
tyrosine kinase (PTK) control in this kit is shown as the activity of
c-Src. The activity of PTK is determined by comparing its
absorbance with that of the PTK standard supplied in the kit. The
measuring range of the kit lies between 32 fmol/well to 2 pmol/
well (from 2.16610
25 U/mL sample to 135610
25 U/ml sample).
The detection sensitivity is 2.16610
25 U/ml and the measurement
range is from 2.16610
252135610
25 U/mL (86.4610
25 to
5,400610
25 U/well).
8.3. Protein assay. The protein content was estimated by
Lowry et al. [22] method using bovine serum albumin as standard.
8.4. Assessment of insulin receptors LAIR and
HAIR. The insulin receptor isoforms, viz., high affinity insulin
receptor (HAIR) and low affinity insulin receptor (LAIR), were
assessed using HPLC. Standards for HAIR (fmol/L, standard
unit) and LAIR (pmol/L, standard unit) were purchased from
Sigma-Aldrich Company (St. Louis, MO, USA). The chro-
matographic conditions were adjusted as follows: the mobile
phase consists of sodium acetate buffer: acetonitrile in the ratio
of 73:27. The buffer was prepared by dissolving 3.0 g of sodium
acetate in 500 ml of HPLC grade water and the pH was
adjusted at 5. The mobile phase was pumped at a flow rate of
1.0 ml/min. The column was maintained at 45uC and the
volume of each injection was 20 ml. Prior to solutions’ injection,
the column was equilibrated for at least 20 min with mobile
phase flowing through the system. The eluents were monitored
at 243 nm, using Beckman gradient liquid chromate-graph with
a dual pump system comprising: Model 126 AA pump, Model
210 sample injection valve: A Rheodyne 20 ml stainless steel
loop injection and Microprocessor system controller. The HPLC
column is an octadecylsilane (C18) reversed phase analytical
partition column (Alltech
,s, 150 mm long64.6 mm internal
diameter, 5.0 mm particle size) and the detector: Model 166-
Beckman UV-Visible spectrophotometer.
9. Statistical Analysis
Results are expressed as means 6 SD of 10 animals, and
differences between groups were tested for significance using
analysis of variance (ANOVA), followed by Tukey-Kramer post hoc
test. Correlation coefficient (r) between HOMA-index and
adiponectin with hepatic adiponectin receptors, insulin receptor
isoforms, protein kinase activity and GLUT2, was carried out in
untreated and treated insulin resistant animals using linear
regression analysis. The level of statistical significance was taken
at P,0.05.
Results
Table 1 reveals that the normal control rats, administered TPM
at both dose levels (40 and 100 mg/kg), showed no significant
difference compared to the normal control group receiving saline.
Therefore, the normal control group, NFD, was chosen for all
statistical comparisons.
Figure 1 depicts the IPGTT performed in untreated HFFD,
topiramate (40 and 100 mg/kg) treated HFFD rats, and normal
control ones. Compared to the normal control group, HFFD diet
elevated serum glucose level markedly after glucose injection, an
effect that leveled off significantly after treatment with either dose
of TPM; these alterations in GTT were imitated by the AUC
values (Table 2). Topiramate treated groups also opposed the
HFFD-induced alterations in insulin-glucose panel as presented in
Table 2, and corrected the lipid profile in a similar pattern
(Figures 2A-C), as well as the ALT level (Figure2-D). As shown in
Figure 2 (E, F), HFFD boosted TNF-a level (14.8 times), but
decreased that of adiponectin (30.4%), respectively. Both TPM40
and TPM100 inhibited the TNF-a level significantly by 30 and
20%, respectively), while raised that of adiponectin, above the
normal level by 2.8 times and 5.6 times, respectively.
HFFD also increased BW, as well as LW/2, VFW/2, and
EFW/2 BW ratios. Albeit TPM100 significantly leveled off all
Table 1. Effect of topiramate on serum and tissue biomarkers of normal control rat.
Normal Control (NFD+saline) Normal Control +TPM40 Normal Control +TPM100
Glucose (mg/dl) 8267.1 85668 6 68
Insulin (mIU/ml) 14.563 16.263 16.864
HOMA-index 2.9760.2 360.5 3.260.4
Fructosamine (nmol/L) 129.4611.6 135.2612 137.5613
AUC 229622 249615 219616
TG (mg/dl) 42644 4 644 5 63
TC (mg/dl) 6165.4 63665 9 65
FFAs (mmol/L) 0.7960.08 0.7260.08 0.8260.1
ALT (IU/L) 40654 2 633 9 64
TNF-a (pg/ml) 1161.5 1261.6 10.560.9
Adiponectin(ng/ml) 1.460.2 1.560.3 1.660.5
BW (g) 250620 240613 232620
LW (g)/BWx100 2.560.15 2.460.2 2.460.3
VFW (g)/BWx100 0.7360.03 0.7560.03 0.7260.02
EFW (g)/BWx100 0.3560.04 0.3760.03 0.360.02
Effect of 14 days administration of topiramate (40, 100 mg/kg) to normal control rats fed normal diet. The following markers were assessed: serum levels of glucose,
insulin, and fructosamine, HOMA-index and area under the curve (AUC); serum triglycerides (TGs), total cholesterol (TC), free fatty acids (FFAs), ALT (IU/L), tumor necrosis
alpha (TNF-a) and adiponectin; body weight (BW) and liver weight (LW)/2, visceral fat weight (VFW)/2 and epididymal fat weight (EFW)/2BW ratio. Values are means
(6 S.D.) of 10 animals. Treatments were administered once daily for 2 weeks. Statistical analysis between groups was carried out using one-way ANOVA followed by
Tukey-Kramer Test, P,0.05.
doi:10.1371/journal.pone.0037757.t001
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(Table 3).
Regarding the hepatic molecular parameters, HFFD increased
the abundance of the two insulin receptor isoforms (Figure 3 A, B),
while significantly lowered those of adiponectin (Figure 3 C, D), as
well as tyrosine kinase activity (Figure 3E) and GLUT2 level
(Figure 3F). The two doses of TPM hampered the HFFD effect on
all these parameters; however, the higher dose showed a more
pronounced effect. Using linear regression analysis, HOMA-index
correlated negatively with hepatic Adipo-R1, Adipo-R2, tyrosine
kinase and GLUT2, and positively with both LAIR and HAIR
(P,0.01). On the contrary, adiponectin correlated positively with
its receptors, tyrosine kinase and GLUT2, while negatively with
insulin receptor isoforms (P,0.001), as shown in Table 4.
Figure 1. The glucose tolerance test (GTT). The curve depicts the changes in serum glucose response in normal control, non-treated obese/
insulin-resistant rats (HFFD), and treated ones by either dose of topiramate (40 & 100 mg/kg;HFFD+TPM40, HFFD+TPM100), after 0, 30, 60, 90, and
120 min following administration of glucose (2 g/kg, ip). Values are means (6 S.D) of 10 animals; as compared with normal control (
*), and HFFD (
{)
groups (one-way ANOVA followed by Tukey–Kramer Test), P,0.05.
doi:10.1371/journal.pone.0037757.g001
Table 2. Effect of topiramate on the indicators of glucose homeostasis of obese/insulin resistant rats.
Glucose (mg/dl) Insulin (mIU/ml) HOMA-index Fructosamine (nmol/L) AUC
Normal Control 8267.1 14.563 2.9760.2 129.4611.6 229622
HFFD 165613
* 35.162
* 14.4761.3
* 191.3613.5
* 546643.0*
HFFD+TPM40 128611
*{ 17.862
{ 5.6960.4
*{ 135.4612.5
{ 312624
*{
HFFD+TPM100 11268
*{{ 15.663
{ 4.3660.3
*{{ 136.8614
{ 269624.9
{
Effect of topiramate (40, 100 mg/kg; TPM40,T P M 100) on serum levels of glucose, insulin, and fructosamine, HOMA-index and area under the curve of the GTT of obese/
insulin resistant rats fed high fat and high fructose diet [HFFD] for 10 weeks. Values are means (6 S.D.) of 10 animals. Treatments were administered once daily for 2
weeks. As compared with normal control (
*), HFFD (
{) and HFFD+TPM40 (
{) groups (one-way ANOVA followed by Tukey–Kramer Test), P,0.05.
doi:10.1371/journal.pone.0037757.t002
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To the best of the authors’ knowledge, this is the first study to
examine the effect of topiramate on the hepatic insulin receptor
isoforms, tyrosine kinase activity, adiponectin receptors and
GLUT2, in a HFFD-induced insulin resistant model. The
subchronic consumption of HFD, containing lard as the main
constituent [23] along with 60% fructose, resulted in obesity/
insulin resistance rat model without overt diabetic state. Such diet
resembles the pathophysiologic scenario of what is known as
‘westernized diet’, which in addition to the sedentary life style is
indicted for the widespread of obesity/insulin resistant cases
nowadays.
The current model has upregulated insulin receptor isoforms,
and decreased adiponectin receptors, tyrosine kinase activity, as
well as GLUT2 level, besides interrupting serum glucose
homeostasis, lipid profile, and adipocytokines. All these changes
were positively modulated by the pre-existence of TPM, which was
reported previously to enhance whole body insulin sensitivity by
increasing glucose disposal, decreasing hepatic glucose output
[11,24] and inhibiting serum FFAs [11].
Figure 2. Effect of topiramate on serum biomarkers. The panels illustrate the effect of topiramate (40 & 100 mg/kg, p.o; TPM40, TPM100)o n
serum (A) triglycerides (TGs, [mg/dl]), (B) total cholesterol(TC, [mg/dl]), (C) free fatty acids (FFAs, mmol/l]), (D)ALT (IU/L), (E) tumor necrosis alpha (TNF-
a, [pg/ml]) and (F) adiponectin [ng/ml] of obese/insulin resistant rats fed high fat and high fructose diet [HFFD] for 10 weeks (mean of 10 animals 6
S.D.). Treatments were administered once daily for 2 weeks. As compared with normal control (
*), HFFD (
{) and HFFD+TPM40
({) groups (one-way
ANOVA followed by Tukey–Kramer Test), P,0.05.
doi:10.1371/journal.pone.0037757.g002
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(Ex11
2) or presence (Ex11
+) of 12 amino acids sequence at the
carboxylic terminus of the a-subunit. The difference is reflected on
the binding affinity to insulin, where the first isoform, is less
abundant in the liver and has higher affinity (HIR-A) to bind with
insulin than HIR-B [25]. However, the expression of these
isoforms is affected by several hormonal and metabolic factors
[26], a fact that applies in the current study, where the insulin-
resistant state induced high abundance of both isoforms. Although
no available data on liver exists, yet previous works point to altered
pattern of insulin receptor isotypes in skeletal muscle of pre-
diabetic IR and NIDDM subjects [27,28], and on isolated
adipocytes of NIDDM patients [29], compared with normal
insulin sensitive counterparts. Sbraccia et al. [30] showed also that
expression of HIR-B correlates positively with hyperinsulinemia
and negatively with insulin sensitivity in cases of insulin resistance.
The present model also inhibited tyrosine kinase activity, a
finding that is corroborated by previous studies in cells of IR
patients [31], and in liver biopsy [32] and skeletal muscles [33] of
obese/T2D patients suggesting that this deficiency contribute to
the I/R characteristics of both abnormalities. Thus, one may
speculate that up-regulation of insulin receptor isoforms is a
compensatory consequence to the model-induced hyperinsulin-
emia, and/or to the inactivated tyrosine kinase, which in turn
impedes the proper autophosphorylation post-receptor cascades.
From these results, it appears that a continuum of receptor and
post-receptor defects are involved in the IR events in the liver of
obese animals. Topiramate, on the other hand, down regulates
insulin receptor isoforms possibly via maintaining insulin sensitiv-
ity, enhancing tyrosine kinase activity and improving glucose
homeostasis, effects that were evidenced in this study.
Furthermore, the current model lowered the content of
GLUT2, which is present mainly in the liver, while pre-treatment
with TPM elevated it. This may be attributed to the improved
insulin sensitivity and the corrected glucose panel, which maintain
the GLUT2 gene expression. It was reported that portal
hyperinsulinemia, in case of I/R, causes a sharp decrease in
hepatic GLUT2 expression [34,35], and proper glucose metabo-
lism is required for the normal expression of the hepatic GLUT2
gene [36]. Although insulin does not affect hepatic glucose
transport directly, yet the expression of some key enzymes,
responsible for glucose metabolism, is under the influence of
insulin [37], and so might GLUT2 [35].
The HFFD-induced hypoadiponectinemia and decreased
expression of its receptors may be explained by the report of
Lonardo et al. [2]. They stated that in clinical conditions such as
T2D and obesity, peripheral IR correlates with hepatic IR and
with hepatic steatosis (HS), an ailment that can be detected in rats
fed even short-term high-fat diets, with the absence of obesity [38].
HS [39] and IR [40,41] are linked with hypoadiponectinemia, and
low levels of Adipo-R2, which is abundant mainly in the liver. HS
is also suggested to cause hepatic IR by stimulating gluconeogen-
esis and activating other protein kinases that may interfere with
tyrosine phosphorylation of insulin receptor substrate-1 (IRS-1)
and IRS-2 and impair the ability of insulin to activate glycogen
synthase and to translocate the glucose transporter GLUT-4 to the
cell surface [2]. These results support the findings of the current
study. Moreover, hypoadiponectinemia may result from obesity-
induced IR in adipose tissue, especially the visceral ones [42]. The
latter, in turn, mediates metabolic alterations in other peripheral
tissues, especially liver and skeletal muscles [41]. Adiponectin,
mediates its biological activity, at least partially, by binding to its
receptors, and correlates to some extent to these receptors that
were identified in 2003 [43]. Previous studies reported that
decreased plasma adiponectin down regulates its receptors in the
skeletal muscles of ob/ob mice [43], and that mice deficient in
Adipo-R1 and R2 showed IR [44], reports that emphasize the
present findings in the liver. On the other hand, the decreased
expression of these receptors is thought to be responsible for the
hypoadiponectinemia, which leads to insulin insensitivity; thus, the
adiponectin/insulin resistance relationship resembles what is
called ‘‘vicious cycle’’ [43].
The mechanisms by which adiponectin ameliorates insulin
sensitivity include increased peripheral glucose uptake, muscle b-
oxidation via the activation of AMP-activated protein kinase,
suppressed hepatic glucose production, besides enhancing insulin-
induced tyrosine phosphorylation of the IR with subsequent
phosphorylation of IRS-1 [45]; nevertheless, the increased
expression of the adiponectin receptors cannot be overruled. All
these effects can, thus, rationalize the improved insulin sensitivity
in the TPM treated groups, where this anticonvulsant boosted up
adiponectin above normal [11,46] and increased the abundance of
its hepatic receptors, as presented in the current study. Topiramate
also upregulates adiponectin gene expression [11,41], which may
be reflected on its receptors, as well. Moreover, in this study, a
direct correlation was observed between the adiponectin receptors
and the tyrosine kinase activity; hence, it is possible that activation
of the hepatic tyrosine kinase may be mediated through the
binding of adiponectin to its receptor(s), an assumption that
remains to be proven.
Although TPM has been reported to decrease food intake and
weight loss, yet it failed in this work to reduce rats’ weight gain
induced by the HFFD, a result that confirms previous murine
studies [15,47,48]. The possible factors of TPM-induced decrease
in food intake, and consequently weight loss, did not play a role in
our findings, since all comparisons made between HFFD+TPM-
treated animals and pair-fed HFFD, regarding food intake were
comparable between the two groups. However, controversial
findings were reported in the literature. Clinically, some authors
concluded that topiramate can significantly reduce body weight in
obese people, with mild to moderate adverse effects [49]. Abo-
Elmatty and Zaitone [50] also demonstrated that 2 months
chronic treatment with topiramate (50 mg/kg), produced a
significant weight loss in obese rats; effects that could be referred
to the chronic topiramate treatment. Topiramate has consistently
decreased the efficacy of energy utilization in animal models, and
effects on food consumption have varied with the model. These
effects on energy efficiency may be mediated by stimulation of
lipoprotein lipase in brown adipose tissue and skeletal muscle, thus
Table 3. Effect of topiramate on body-, liver- and fat weights
of obese/insulin resistant rats.
BW (g) LW/BW x100 VFW/BWx100
EFW/
BWx100
Normal Control 250620 2.560.15 0.7360.03 0.3560.04
HFFD group 348635
* 3.1861.27
* 1.0160.09
* 0.7860.08
*
HFFD+TPM40 347.5637
* 2.9060.2
* 0.8560.1 0.6860.07
*
HFFD+TPM100 325640
* 2.6960.2
{ 0.7860.04
{ 0.5660.06
{
Effect of topiramate (40, 100 mg/kg; TPM40,T P M 100) on body weight (BW) and
liver weight (LW)/2, visceral fat weight (VFW)/2 and epididymal fat weight
(EFW)/2BW ratio of obese/insulin resistant rats fed high fat and high fructose
diet [HFFD] for 10 weeks. Values are means (6 S.D.) of 10 animals. Treatments
were administered once daily for 2 weeks. As compared with normal control (
*),
and HFFD (
{) groups (one-way ANOVA followed by Tukey-Kramer Test), P,0.05.
doi:10.1371/journal.pone.0037757.t003
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hepatic (A, B) insulin receptor isoforms (high affinity, [HAIR, fmol/mg protein] and low affinity [LAIR, pmol/mg protein] insulin receptor), (C, D)
adiponectin receptors (Adipo-R1, Adipo-R2 [ng/mg protein]), (E) protein tyrosine kinase (PTK [U/mg protein]), and (F) glucose transporter-2 (GLUT2
[mg/mg protein]) of obese/insulin resistant rats fed high fat and high fructose diet [HFFD] for 10 weeks (mean of 10 animals 6 S.D.). Treatments were
administered once daily for 2 weeks. As compared with normal control (
*), HFFD (
{) and HFFD+TPM40
({) groups (one-way ANOVA followed by Tukey–
Kramer Test), P,0.05.
doi:10.1371/journal.pone.0037757.g003
Table 4. Correlation coefficient (r) between HOMA-I and serum adiponectin with hepatic GLUT2, adiponectin receptors (Adipo- R1,
R2), insulin receptor isoforms (LAIR, HAIR), and tyrosine kinase.
GLUT2 Adipo-R1 Adipo-R2 LAIR HAIR Tyrosine kinase
HOMA –I 20.645
** P=0.004 20678
** P=0.002 20807
** P=0.000 0.649
** P=0.004 0.840
** P=0.000 20.767
** P=0.000
Adiponectin 0.824
** P=0.000 0.942
** P=0.000 0.893
** P=0.000 20.937
** P=0.000 20.960
** P=0.000 0.912
** P=0.000
Correlation was carried out in untreated and treated hyperglycemic animals.
doi:10.1371/journal.pone.0037757.t004
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uncoupling proteins 2 and 3 [49], thus directly decreasing the
efficiency of energy utilization [51].
The anticonvulsant-mediated insulin sensitivity may correlate
partly to the decrease in the VFW- and EFW2/body weight
ratios, where visceral obesity [52] and white adipose tissue (WAT)
are decisive steps in insulin resistance emerging. Epididymal fat
tissue, akin to WAT, mediates chronic inflammatory reactions and
releases macrophages, which sequentially discharge a pro-inflam-
matory adipokine, TNF-a; the latter enhances adipocytes to
produce chemokines that aid in the recruitment of further
macrophages in a ceaseless cycle [53]. TNF-a, elevated in the
current study, induces IR by several mechanisms, including the
down-regulation of adiponectin expression and inactivation of
tyrosine kinase [54] and is responsible, partly, for hepatic fatty
changes [2] characterized by elevated ALT. This enzyme is found
primarily in the liver and is considered an indicator of
hepatocellular health that can be compromised in case of obesity
and IR [55], facts that coincide with the current results. It is also
possible that high ALT reflects impaired insulin signaling, even if it
is not associated with liver injury, where insulin inhibits
gluconeogenic enzymes, including ALT [56]. Thus, the TPM-
induced low ALT activity may be mediated by the improvement of
insulin sensitivity, rather than by the lowering of TNF-a, which
was significant yet subtle, as shown in Figure 2E.
Hepatic insulin resistance also enhances lipogenesis, events that
can suggest a direct association between IR and fatty changes [57],
along with raised ALT. In the present work, TPM hindered the
model-induced lipid profile alterations, where it decreased levels of
serum FFAs, TGs and TC. In a previous study, Liang et al. [57]
reported that TPM regulates hepatic expression of genes involved
in lipid metabolism, which could be part of the mechanisms by
which TPM reduces plasma FFAs and TG levels in obese diabetic
rodents. TPM reduces enzymes responsible for fatty acids synthesis
and enhances those of fatty acid b-oxidation [57], as well as
mitochondrial function [58], which accelerates the b-oxidation
rate of fatty acids. Albeit scarce data are available regarding the
effect of TPM on TC level, yet previous studies support our
finding, where TC level was decreased in epileptic adults treated
with TPM [59], and migraine patients receiving TPM [60] and
alcoholic patients subjected to TPM [61]. However, the exact
mechanism for this effect has not been clearly elucidated.
In conclusion, the results of the present study re-emphasize the
vital role of the liver tissue in insulin resistance disorder, and
confirm that the insulin-sensitizing effect of TPM involves
mending hepatic alterations in obese/insulin resistant rats, besides
its known correcting effect on hyperinsulinemia, dyslipidemia, and
glucose intolerance.
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